ATE378047T1 - Benzothiazol-derivate zur behandlung von diabetes - Google Patents
Benzothiazol-derivate zur behandlung von diabetesInfo
- Publication number
- ATE378047T1 ATE378047T1 AT04787110T AT04787110T ATE378047T1 AT E378047 T1 ATE378047 T1 AT E378047T1 AT 04787110 T AT04787110 T AT 04787110T AT 04787110 T AT04787110 T AT 04787110T AT E378047 T1 ATE378047 T1 AT E378047T1
- Authority
- AT
- Austria
- Prior art keywords
- unsubstituted
- substituted
- treatment
- benzothiazole derivatives
- group
- Prior art date
Links
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03102740 | 2003-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE378047T1 true ATE378047T1 (de) | 2007-11-15 |
Family
ID=34306921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04787110T ATE378047T1 (de) | 2003-09-12 | 2004-09-08 | Benzothiazol-derivate zur behandlung von diabetes |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20070088017A1 (de) |
| EP (1) | EP1696909B1 (de) |
| JP (1) | JP5021307B2 (de) |
| AT (1) | ATE378047T1 (de) |
| AU (1) | AU2004271740B2 (de) |
| CA (1) | CA2534314C (de) |
| CY (1) | CY1107820T1 (de) |
| DE (1) | DE602004010178T2 (de) |
| DK (1) | DK1696909T3 (de) |
| ES (1) | ES2297494T3 (de) |
| HR (1) | HRP20070527T3 (de) |
| IL (1) | IL174250A (de) |
| NO (1) | NO20061600L (de) |
| PL (1) | PL1696909T3 (de) |
| PT (1) | PT1696909E (de) |
| SI (1) | SI1696909T1 (de) |
| WO (1) | WO2005025567A1 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7838522B2 (en) * | 2004-11-17 | 2010-11-23 | Ares Trading S.A. | Benzothiazole formulations and use thereof |
| BRPI0613042A2 (pt) | 2005-07-15 | 2010-12-14 | Serono Lab | inibidores de jnk para o tratamento de endometriose |
| KR20080044836A (ko) | 2005-07-15 | 2008-05-21 | 라보라뚜와르 세로노 에스. 에이. | 자궁내막증 치료용 ｊｎｋ 억제제 |
| EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
| WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2377530A3 (de) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation von Neurogenese durch PDE-Hemmung |
| EP1942879A1 (de) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2021000A2 (de) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenese mittels angiotensin-modulation |
| DK2054049T3 (en) | 2006-08-24 | 2016-08-01 | Univ Tennessee Res Found | SUBSTITUTED ACYLANILIDES AND PROCEDURES FOR USING THEREOF |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2008125518A2 (en) * | 2007-04-17 | 2008-10-23 | Merck Serono S.A. | Process for the preparation of piperazine benzothiazoles |
| UA100527C2 (en) * | 2007-10-10 | 2013-01-10 | Астразенека Аб | Benzothiazoles as ghrelin receptor modulators |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| PL2872482T3 (pl) | 2012-07-13 | 2021-03-08 | Oncternal Therapeutics, Inc. | Sposób leczenia raków sutka z użyciem selektywnego modulatora receptora androgenowego (sarm) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| CN104903331A (zh) * | 2013-01-24 | 2015-09-09 | 山东亨利医药科技有限责任公司 | Jnk抑制剂 |
| WO2017025980A2 (en) * | 2015-08-12 | 2017-02-16 | Shoolineuniversity Of Biotechnology And Management Sciences | Novel benzothiazole derivatives with enhanced biological activity |
| CN115887434B (zh) * | 2022-11-23 | 2024-12-24 | 四川大学 | 具有抗氧化作用的药物用于制备治疗多囊卵巢综合征药物的用途 |
| US11970467B1 (en) | 2023-10-13 | 2024-04-30 | King Faisal University | N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound |
| US11905260B1 (en) | 2023-10-13 | 2024-02-20 | King Faisal University | N′-(1-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as an antimicrobial compound |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1176269A (en) * | 1981-03-02 | 1984-10-16 | Kazimir Sestanj | N-naphthoylglycine derivatives |
| US4927831A (en) * | 1988-10-20 | 1990-05-22 | American Home Products | Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors |
| US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| EP1110957A1 (de) * | 1999-12-24 | 2001-06-27 | Applied Research Systems ARS Holding N.V. | Benzazolderivate und ihre Verwendung als JNK Modulatoren |
| EP1450792B1 (de) * | 2001-12-07 | 2006-09-27 | Applied Research Systems ARS Holding N.V. | Benzazole derivate zur behandlung von scleroderma |
| RS51407B (sr) * | 2002-04-25 | 2011-02-28 | Laboratoires Serono Sa | Piperazinski benzotijazoli kao agensi za lečenje cerabralnih ishemičnih poremećaja ili poremećaja cns |
-
2004
- 2004-09-08 EP EP04787110A patent/EP1696909B1/de not_active Expired - Lifetime
- 2004-09-08 HR HR20070527T patent/HRP20070527T3/xx unknown
- 2004-09-08 PT PT04787110T patent/PT1696909E/pt unknown
- 2004-09-08 DK DK04787110T patent/DK1696909T3/da active
- 2004-09-08 PL PL04787110T patent/PL1696909T3/pl unknown
- 2004-09-08 JP JP2006525827A patent/JP5021307B2/ja not_active Expired - Fee Related
- 2004-09-08 DE DE602004010178T patent/DE602004010178T2/de not_active Expired - Lifetime
- 2004-09-08 ES ES04787110T patent/ES2297494T3/es not_active Expired - Lifetime
- 2004-09-08 SI SI200430550T patent/SI1696909T1/sl unknown
- 2004-09-08 AT AT04787110T patent/ATE378047T1/de active
- 2004-09-08 WO PCT/EP2004/052090 patent/WO2005025567A1/en not_active Ceased
- 2004-09-08 US US10/571,291 patent/US20070088017A1/en not_active Abandoned
- 2004-09-08 AU AU2004271740A patent/AU2004271740B2/en not_active Ceased
- 2004-09-08 CA CA2534314A patent/CA2534314C/en not_active Expired - Fee Related
-
2006
- 2006-03-12 IL IL174250A patent/IL174250A/en not_active IP Right Cessation
- 2006-04-07 NO NO20061600A patent/NO20061600L/no not_active Application Discontinuation
-
2007
- 2007-12-04 CY CY20071101543T patent/CY1107820T1/el unknown
-
2013
- 2013-10-08 US US14/048,690 patent/US20140107116A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SI1696909T1 (sl) | 2008-02-29 |
| DE602004010178T2 (de) | 2008-09-11 |
| WO2005025567A1 (en) | 2005-03-24 |
| PT1696909E (pt) | 2007-12-21 |
| DE602004010178D1 (de) | 2007-12-27 |
| AU2004271740A1 (en) | 2005-03-24 |
| EP1696909A1 (de) | 2006-09-06 |
| CA2534314C (en) | 2012-11-13 |
| DK1696909T3 (da) | 2008-01-02 |
| CY1107820T1 (el) | 2013-06-19 |
| HK1096594A1 (en) | 2007-06-08 |
| HRP20070527T3 (en) | 2007-12-31 |
| AU2004271740B2 (en) | 2010-10-28 |
| ES2297494T3 (es) | 2008-05-01 |
| EP1696909B1 (de) | 2007-11-14 |
| US20070088017A1 (en) | 2007-04-19 |
| JP2007505083A (ja) | 2007-03-08 |
| PL1696909T3 (pl) | 2008-04-30 |
| IL174250A (en) | 2011-01-31 |
| NO20061600L (no) | 2006-04-07 |
| CA2534314A1 (en) | 2005-03-24 |
| JP5021307B2 (ja) | 2012-09-05 |
| US20140107116A1 (en) | 2014-04-17 |
| IL174250A0 (en) | 2006-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107820T1 (el) | Παραγωγα βενζοθειαζολιου για την θεραπευτικη αντιμετωπιση του διαβητη | |
| ATE557030T1 (de) | Kondensiertes heterocyclisches derivat, dieses enthaltende medizinische zusammensetzung und deren medizinische verwendung | |
| NO20051209L (no) | Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme | |
| BRPI0406761A (pt) | Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia | |
| NO20080789L (no) | 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid | |
| DE60325740D1 (de) | Verwendung von protein-kinase-n-beta | |
| SE0102299D0 (sv) | Compounds | |
| NO20080728L (no) | Nye 1,4-benzotiazepin-1,1-dioksidderivater som har forbedrede egenskaper, fremgangsmate for fremstilling derav, medikamenter inneholdende nevnte forbindelsene og anvendelse derav | |
| CY1112466T1 (el) | ΠΥΡΡΟΛΙΔΙΝΟΝΕΣ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΜΕ ΠΙΠΕΡΙΔΙΝΥΛΙΟ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ 11-β-ΥΔΡΟΞΥΣΤΕΡΟΕΙΔΟΥΣ ΑΦΥΔΡΟΓΟΝΑΣΗΣ 1 | |
| CY1107398T1 (el) | Νεα διφαινυλαζητιδoνη με βελτιωμενες φυσιολογικες ιδιοτητες, η διαδικασια για την παραγωγη της, το φαρμακευτικο παρασκευασμα που περιεχει τις ενωσεις αυτες καθως και η χρηση του | |
| BRPI0509573A (pt) | derivados de sulfonamida-tiazolpiridina como ativadores de glicocinase úteis para o tratamento de diabetes do tipo 2 | |
| NO20054713L (no) | C-glycosidderivater og salter derav | |
| NO20061153L (no) | Trans-1-(6-klor-3-fenylindan-1-yl)-3,3-dimetylpiperazin | |
| ATE455772T1 (de) | Alkinylarylcarbonsäureamide | |
| BRPI0519329A2 (pt) | Ácidos hidroxibifenil carboxÍlicos e derivados, mÉtodos para produÇço dos mesmos e uso dos mesmos | |
| NO20061614L (no) | Benzimidazolacetonitriler | |
| ATE548032T1 (de) | Verwendung von chlorguanabenzderivaten zur behandlung von mit polyglutaminexpansion assoziierten erkrankungen | |
| ATE406894T1 (de) | 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer | |
| MA28339A1 (fr) | Derives de l'acide 7- amino-4-quinolone-3-carboxylique substitues de maniere heterocyclique, methode pour leur production et leur utilisation en tant que medicaments | |
| NO20061599L (no) | Benzoksazol acetonitriler | |
| DK1656139T3 (da) | Aryldicarboxamider | |
| DE602005024384D1 (de) | Neue verbindungen, ihre herstellung und verwendung | |
| BRPI0607558A2 (pt) | derivados do ácido aminobutanóico, inibidor da carnitina palmitoil transferase(cpt) | |
| NO20055205L (no) | 4-(2-fcnylsulfanyl-fenyl)-1,2,3,6-tydropyridinderivater som serotoniniopptaksinhibitorer | |
| TW200609228A (en) | Substituted n-acyl-2-aminothiazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1696909 Country of ref document: EP |
|
| EEFA | Change of the company name |